NewsOur news NewsBioVersys Joins Eu-Funded RespiriNTM Programme to Accelerate Development of its Broad-Spectrum Drug Candidates Against NTM Pulmonary DiseasesNewsBioVersys Announces Last Patient Last Visit in BV100 Phase 2 Clinical Trial in Ventilator Associated Bacterial Pneumonia (VABP) and Provides a Business UpdateNewsNATURE REVIEWS HIGHLIGHTS SIGNIFICANT SUCCESSES OF ANTIBIOTIC COLLABORATION AND CALLS FOR SUSTAINABLE R&D FUNDING SCHEMESNewsBioVersys Announces Strategic Investment from GIBF2 and Launch of BV100 Clinical Program in ChinaNewsBioversys Awarded Non-Dilutive Funding from CF AMR Syndicate Collaborative Discovery ProgrammeNewsBioVersys Announces Expansion of Strategic Collaboration with GSK and Extension of its Series C Round by CHF 12.3 MillionNewsBioVersys and GSK successfully complete IMI2 programme reaching clinical MilestoneNewsBioversys AG and Helmholtz Centre for infection research join forces to accelerate AMR research and developmentNewsBioVersys receives U.S. FDA orphan-drug designation for alpibectir and ethionamide fixed-dose combination for treatment of tuberculosis 123…56Next »
NewsBioVersys Joins Eu-Funded RespiriNTM Programme to Accelerate Development of its Broad-Spectrum Drug Candidates Against NTM Pulmonary Diseases
NewsBioVersys Announces Last Patient Last Visit in BV100 Phase 2 Clinical Trial in Ventilator Associated Bacterial Pneumonia (VABP) and Provides a Business Update
NewsNATURE REVIEWS HIGHLIGHTS SIGNIFICANT SUCCESSES OF ANTIBIOTIC COLLABORATION AND CALLS FOR SUSTAINABLE R&D FUNDING SCHEMES
NewsBioVersys Announces Strategic Investment from GIBF2 and Launch of BV100 Clinical Program in China
NewsBioVersys Announces Expansion of Strategic Collaboration with GSK and Extension of its Series C Round by CHF 12.3 Million
NewsBioversys AG and Helmholtz Centre for infection research join forces to accelerate AMR research and development
NewsBioVersys receives U.S. FDA orphan-drug designation for alpibectir and ethionamide fixed-dose combination for treatment of tuberculosis
